SIGA Technologies Reports Q3 2026 Results Amid Completion of Major Government Delivery Cycles
SIGA Technologies reported a significant decline in third-quarter revenue, falling to $1.3 million from $2.6 million in the prior-year period. This downturn was primarily driven by lower product sales volumes and zero customer deliveries during the quarter as the company finalized major procurement obligations under its BARDA 19C contract with the U.S. Strategic National Stockpile. Despite the revenue drop, the company's net loss narrowed to $2.9 million compared to a $6.4 million loss in the same period last year. Looking forward, SIGA secured a new Canadian contract valued at up to $15 million over five years and is awaiting Phase I pediatric study results due by late 2026. However, management warned of an unpredictable U.S. government procurement timeline and a delay in its Post-Exposure Prophylaxis sNDA filing until 2028 due to additional FDA requirements.
Tickers: $SIGA
Topics: net loss narrowing product sales volume R&D revenue revenue decline